A phase 2 clinical trial of DD 01 for the treatment of obese patients with both diabetes and nonalcoholic fatty liver disease (NAFLD)
Latest Information Update: 22 Oct 2021
Price :
$35 *
At a glance
- Drugs DD 01 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 22 Oct 2021 New trial record
- 19 Oct 2021 According to a D and D Pharmatech media release, company has completed a $51 million Series C round of financing.Proceeds will be used for this trial.